|Bid||5.23 x 1200|
|Ask||5.24 x 800|
|Day's Range||5.08 - 5.61|
|52 Week Range||2.24 - 8.44|
|Beta (3Y Monthly)||3.97|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||9.67|
NEW YORK, NY / ACCESSWIRE / December 11, 2018 / Wall Street bounced on Monday as optimism outweighed earlier losses caused by the U.S. - China trade dispute. Analysts expect the Federal Reserve to raise ...
Avid Bioservices (CDMO) delivered earnings and revenue surprises of 33.33% and -5.32%, respectively, for the quarter ended October 2018. Do the numbers hold clues to what lies ahead for the stock?
The Tustin, California-based company said it had a loss of 5 cents per share. Losses, adjusted to account for discontinued operations, were 6 cents per share. The results beat Wall Street expectations. ...
-- Fiscal 2019 Projected Revenue of $51 to $55 Million Reaffirmed -- -- Signed Project Expansion Orders for $6.3 Million with Current Customers -- -- Successfully Executed.
Biotech stocks pulled back in last week. Incidentally, some large-cap biotech stocks were hitting new peaks even amid the sectoral downturn. New molecular entity approval hit a new peak at 55 thus far ...
TUSTIN, Calif., Dec. 05, 2018 -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated contract development and manufacturing organization (CDMO) working to improve.
Avid Bioservices (CDMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TUSTIN, Calif., Dec. 03, 2018 -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated contract development and manufacturing organization (CDMO) working to improve.
Avid Bioservices (CDMO) needs investors to pay close attention to the stock based on moves in the options market lately.
TUSTIN, Calif., Sept. 20, 2018-- Avid Bioservices, Inc., a dedicated biologics contract development and manufacturing organization working to improve patient lives by providing high quality development ...
NEW YORK, NY / ACCESSWIRE / September 11, 2018 / Acorda shares were deep in the red after a disappointing court ruling on Monday. A U.S. District Court of Appeals has held up a lower court ruling invalidating key patents on Ampyra, the company’s multiple sclerosis drug that accounts for most of its sales. Shares of Avid Bioservices traded fairly flat during the day but soared in after-hours extended trading after reporting stellar first quarter financial results.
Avid Bioservices (CDMO) delivered earnings and revenue surprises of 33.33% and 26.52%, respectively, for the quarter ended July 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Tustin, California-based company said it had a loss of 6 cents. The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
A newer class of drugs called Cell Therapies offer major advances for some diseases, and this therapy type is expected to boom in the next ten years to a multi-billion dollar market. Top drug companies will benefit significantly, but many will outsource the complicated manufacturing process for these drugs. The companies that do the manufacturing stand to benefit as more of these drugs are developed and approved, possibly saving money for both the healthcare system and drug companies.
LONDON, UK / ACCESSWIRE / July 19, 2018 / If you want a free Stock Review on CDMO sign up now at www.wallstequities.com/registration. All you have to do is sign up today for this free limited time offer by clicking the link below.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling the Peaks (Stocks hitting 52-week highs on July 17) Avid Bioservices Inc (NASDAQ: CDMO )( reversed to a profit ...
NEW YORK, NY / ACCESSWIRE / July 18, 2018 / Johnson & Johnson saw a pop after announcing second quarter results and vowing to appeal a court order last week that ordered the company to pay a whopping $4.69 billion to nearly two dozen women who alleged the company's talc products contained asbestos and caused them to develop ovarian cancer. Shares of Avid Bioservices also saw big gains after announcing a new CFO. Johnson & Johnson shares saw a gain of 3.54% by the close on Tuesday on trading volume nearly double compared to usual.
Avid Bioservices, Mellanox, Berkshire Hathaway, Intel and Chevron highlighted as Zacks Bull and Bear of the Day